Growth hormone therapy improves growth in children with cystic fibrosis related liver disease

Journal of Pediatric Endocrinology and Metabolism

Volumn 21, Issue 8, 2008, Pages 793-797

  Stalvey, Michael S ^a,b   Torrez, Daniel M ^a   Hillan, Jennifer ^a   Gonzalez Peralta, Regino P ^a   Haafiz, Allah ^a   Rosenbloom, Arlan L ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Cystic fibrosis; Growth hormone; Insulin like growth factor I; Liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CLONIDINE; GLUCAGON; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TRANSMEMBRANE CONDUCTANCE REGULATOR;

AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE REPORT; CHRONIC LIVER DISEASE; CYSTIC FIBROSIS; DRUG DOSE INCREASE; DRUG SAFETY; ENDOCRINE FUNCTION TEST; FEMALE; GROWTH DISORDER; GROWTH RATE; HEPATOMEGALY; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INFANT; JAUNDICE; LIVER DISEASE; LIVER DYSFUNCTION; LIVER FUNCTION; LIVER TRANSPLANTATION; LUNG DISEASE; MALE; PRESCHOOL CHILD; TOTAL PARENTERAL NUTRITION; WEIGHT GAIN;

EID: 52649156024     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2008.21.8.793     Document Type: Article

References (31)

1. Orenstein DM, Winnie GB, Altman H. Cystic fibrosis: a 2002 update. J Pediatr 2002; 140: 156-164.
2. Foundation CF. Patient Registry 2005 Annual Report. Bethesda, MD, 2006.
3. Virella-Lowell I, Herlihy JD, Liu B, Lopez C, Cruz P, Muller C, Baker HV, Flotte TR. Effects of CFTR, interieukin-10, and Pseudomonas aeruginosa on gene expression profiles in a CF bronchial epithelial cell Line. Mol Ther 2004; 10: 562-573.
4. Sagel SD, Accurso FJ. Monitoring inflammation in CF. Cytokines. Clin Rev Allergy Immunol 2002; 23: 41-57.
5. Stalvey MS, Muller C, Schatz DA, Wasserfall CH, Campbell-Thompson ML, Theriaque DW, Flotte TR, Atkinson MA. Cystic fibrosis transmembrane conductance regulator deficiency exacerbates islet cell dysfunction after beta-cell injury. Diabetes 2006; 55: 1939-1945.
6. Konstan MW, Butler SM, Wohl ME, Stoddard M, Matousek R, Wagener JS, Johnson CA, Morgan WJ; Investigators and Coordinators of the Epidemiologic Study of Cystic Fibrosis. Growth and nutritional indexes in early life predict pulmonary function in cystic fibrosis. J Pediatr 2003; 142: 624-630.
7. Beker LT, Russek-Cohen E, Fink RJ. Stature as a prognostic factor in cystic fibrosis survival. J Am Diet Assoc 2001; 101: 438-442.
8. Laursen EM, Lanng S, Rasmussen MH, Koch C, Skakkebaek NE, Muller J. Normal spontaneous and stimulated GH levels despite decreased IGF-I concentrations in cystic fibrosis patients. Eur J Endocrinol 1999; 140: 315-321.
9. Wu YL, Ye J, Zhang S, Zhong J, Xi RP. Clinical significance of serum IGF-I, IGF-II and IGFBP-3 in liver cirrhosis. World J Gastroenterol 2004; 10: 2740-2743.
10. Rosenbloom AL. Physiology and disorders of the growth hormone receptor (GHR) and GH-GHR signal transduction. Endocrine 2000; 12: 107-119.
11. Hardin DS, Ferkol T, Ahn C, Dreimane D, Dyson M, Morse M, Prestidge C, Rice J, Seilheimer DK. A retrospective study of growth hormone use in adolescents with cystic fibrosis. Clin Endocrinol (Oxf) 2005; 62: 560-566.
12. Hardin DS, Adams-Huet B, Brown D, Chatfield B, Dyson M, Ferkol T, Howenstine M, Prestidge C, Royce F, Rice J, Seilheimer DK, Steelman J, Shepherds R. Growth hormone treatment improves growth and clinical status in prepubertal children with cystic fibrosis: results of a multicenter randomized controlled trial. J Clin Endocrinol Metab 2006; 91: 49254929.
13. Shead EF, Haworth CS, Condliffe AM, McKeon DJ, Scott MA, Compston JE. Cystic fibrosis transmembrane conductance regulator (CFTR) is expressed in human bone. Thorax 2007; 62: 650-651.
14. Domene HM, Bengolea SV, Jasper HG, Boisclair YR. Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse. J Endocrinol Invest. 2005; 28 (Suppl): 43-46.
15. Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D, Rosenfeld RG. Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab 2006; 91: 1826-1831.
16. Domené HM, Bengolea SV, Martinez AS, Ropelato MG, Pennisi P, Scaglia P, Heinrich JJ, Jasper HG. Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004; 350: 570-577.
17. Domené HM, Martinez AS, Frystyk J, Bengolea SV, Ropelato MG, Scaglia PA, Chen JW, Heuck C, Wolthers OD, Heinrich JJ, Jasper HG. Normal growth spurt and final height despite low levels of all forms of circulating insulin-like growth factor-I in a patient with acid-labile subunit deficiency. Horm Res 2007; 67: 243-249.
18. Spray CH, McKiernan P, Waldron KE, Shaw N, Kirk J, Kelly DA. Investigation and outcome of neonatal hepatitis in infants with hypopituitarism. Acta Paediatr 2000; 89: 951-954.
19. Choo-Kang LR, Sun CC, Counts DR. Cholestasis and hypoglycemia: manifestations of congenital anterior hypopituitarism. J Clin Endocrinol Metab 1996; 81: 2786-2789.
20. Pennisi PA, Kopchick JJ, Thorgeirsson S, LeRoith D, Yakar S. Role of growth hormone (GH) in liver regeneration. Endocrinology 2004; 145: 4748-4755.
21. Desbois-Mouthon C, Wendum D, Cadoret A, Rey C, Leneuve P, Blaise A, Housset C, Tronche F, Le Bouc Y, Holzenberger M. Hepatocyte proliferation during liver regeneration is impaired in mice with liver-specific IGF-1R knockout. FASEB J 2006; 20: 773-775.
22. Scolapio JS, Camilleri M, Fleming CR, Oenning LV, Burton DD, Sebo TJ, Batts KP, Kelly DG. Effect of growth hormone, glutamine, and diet on adaptation in short-bowel syndrome: a randomized, controlled study. Gastroenterology 1997; 113: 1074-1081.
23. Szkudlarek J, Jeppesen PB, Mortensen PB. Effect of high dose growth hormone with glutamine and no change in diet on intestinal absorption in short bowel patients: a randomised, double blind, crossover, placebo controlled study. Gut 2000; 47: 199-205.
24. Byrne TA, Wilmore DW, Iyer K, Dibaise J, Clancy K, Robinson MK, Chang P, Gertner JM, Lautz D. Growth hormone, glutamine, and an optimal diet reduces parenteral nutrition in patients with short bowel syndrome: a prospective, randomized, placebo-controlled, double-blind clinical trial. Ann Surg 2005; 242: 655-661.
25. Migliaccio-Walle K, Caro JJ, Moller J. Economic implications of growth hormone use in patients with short bowel syndrome. Curr Med Res Opin 2006; 22: 2055-2063.
26. Shulman DI, Hu CS, Duckett G, Lavallee-Grey M. Effects of short-term growth hormone therapy in rats undergoing 75% small intestinal resection. J Pediatr Gastroenterol Nutr 1992; 14: 3-11.
27. Zhou X, Li YX, Li N, Li JS. Glutamine enhances the gut-trophic effect of growth hormone in rat after massive small bowel resection. J Surg Res 2001; 99: 47-52.
28. Ladd AP, Grosfeld JL, Pescovitz OH, Johnson NB. The effect of growth hormone supplementation on late nutritional independence in pediatric patients with short bowel syndrome. J Pediatr Surg 2005; 40: 442-445.
29. Nucci AM, Finegold DN, Yaworski JA, Kowalski L, Barksdale EM Jr. Results of growth trophic therapy in children with short bowel syndrome. J Pediatr Surg 2004; 39: 335-339; discussion 335-339.
30. Moyle GJ, Daar ES, Gertner JM, Kotler DP, Melchior JC, O'Brien F, Svanberg E; Serono 9037 Study Team. Growth hormone improves lean body mass, physical performance, and quality of life in subjects with HIV-associated weight loss or wasting on highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004; 35: 367-375.
31. Wallace JD, Abbott-Johnson WJ, Crawford DH, Barnard R, Potter JM, Cuneo RC. GH treatment in adults with chronic liver disease: a randornized, double-blind, place bo-controlled, cross-over study. J Clin Endocrinol Metab 2002; 87: 2751-2759.